February 20, 2020 Synthetic Biologics Reports 2019 Year End Operational Highlights and Financial Results
February 13, 2020 Synthetic Biologics to Report 2019 Year End Operational Highlights and Financial Results on February 20, 2020
January 7, 2020 Synthetic Biologics Receives FDA Guidance at Type C Meeting for SYN-004 (ribaxamase) Phase 1b/2a Clinical Trial in Allogeneic HCT Recipients
